Research
Molecular
There is a surge of interest in unimolecular peptide hormone-based polypharmacy for obesity management.
Practitioners should stay informed about developments in peptide hormone therapies for obesity.
StrongSupportsmedium confidence
there has been a recent surge of interest in pursuit of both administration of individual peptide combinations as well as development of unimolecular peptide hormone-based polypharmacy.
Why this rating
The claim is based on emerging research trends.
Source
Is polypharmacy the future for pharmacological management of obesity?
Ryan A. Lafferty et al. · Current Opinion in Endocrine and Metabolic Research · 2022
DOI 10.1016/j.coemr.2022.100322
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →